Literature DB >> 19164148

Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.

Françoise Banères-Roquet1, Maxime Gualtieri, Philippe Villain-Guillot, Martine Pugnière, Jean-Paul Leonetti.   

Abstract

The pharmacologic effect of an antibiotic is directly related to its unbound concentration at the site of infection. Most commercial antibiotics have been selected in part for their low propensity to interact with serum proteins. These nonspecific interactions are classically evaluated by measuring the MIC in the presence of serum. As higher-throughput technologies tend to lose information, surface plasmon resonance (SPR) is emerging as an informative medium-throughput technology for hit validation. Here we show that SPR is a useful automatic tool for quantification of the interaction of model antibiotics with serum proteins and that it delivers precise real-time kinetic data on this critical parameter.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164148      PMCID: PMC2663126          DOI: 10.1128/AAC.00971-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.

Authors:  A Frostell-Karlsson; A Remaeus; H Roos; K Andersson; P Borg; M Hämäläinen; R Karlsson
Journal:  J Med Chem       Date:  2000-05-18       Impact factor: 7.446

2.  Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis.

Authors:  J D Huang
Journal:  J Pharm Sci       Date:  1983-11       Impact factor: 3.534

Review 3.  Protein binding displacement interactions and their clinical importance.

Authors:  J C McElnay; P F D'Arcy
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

4.  Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone.

Authors:  K J Fehske; U Schläfer; U Wollert; W E Müller
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

5.  Structural basis of the drug-binding specificity of human serum albumin.

Authors:  Jamie Ghuman; Patricia A Zunszain; Isabelle Petitpas; Ananyo A Bhattacharya; Masaki Otagiri; Stephen Curry
Journal:  J Mol Biol       Date:  2005-10-14       Impact factor: 5.469

6.  Effect of human plasma on the antimicrobial activity of iclaprim in vitro.

Authors:  H Laue; T Valensise; A Seguin; S Hawser; S Lociuro; K Islam
Journal:  J Antimicrob Chemother       Date:  2007-10-19       Impact factor: 5.790

7.  Influence of protein binding on therapeutic efficacy of cefoperazone.

Authors:  L R Peterson; J A Moody; C E Fasching; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

8.  Impact of plasma protein binding on antimicrobial activity using time-killing curves.

Authors:  M A Zeitlinger; R Sauermann; F Traunmüller; A Georgopoulos; M Müller; C Joukhadar
Journal:  J Antimicrob Chemother       Date:  2004-10-07       Impact factor: 5.790

9.  Conformation selectivity in the binding of diazepam and analogues to alpha1-acid glycoprotein.

Authors:  Ilona Fitos; Júlia Visy; Ferenc Zsila; György Mády; Miklós Simonyi
Journal:  Bioorg Med Chem       Date:  2007-05-03       Impact factor: 3.641

10.  Stereospecific and competitive binding of drugs to human serum albumin: a difference circular dichroism approach.

Authors:  G Ascoli; C Bertucci; P Salvadori
Journal:  J Pharm Sci       Date:  1995-06       Impact factor: 3.534

View more
  2 in total

1.  Study of β-lactam-based drug interaction with albumin protein using optical, sensing, and docking methods.

Authors:  Hannaneh Monirinasab; Mostafa Zakariazadeh; Havva Kohestani; Morteza Kouhestani; Farzaneh Fathi
Journal:  J Biol Phys       Date:  2022-01-30       Impact factor: 1.560

2.  Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19.

Authors:  Ting Shu; Wanshan Ning; Di Wu; Jiqian Xu; Qiangqiang Han; Muhan Huang; Xiaojing Zou; Qingyu Yang; Yang Yuan; Yuanyuan Bie; Shangwen Pan; Jingfang Mu; Yang Han; Xiaobo Yang; Hong Zhou; Ruiting Li; Yujie Ren; Xi Chen; Shanglong Yao; Yang Qiu; Ding-Yu Zhang; Yu Xue; You Shang; Xi Zhou
Journal:  Immunity       Date:  2020-10-20       Impact factor: 31.745

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.